Dimensional Fund Advisors LP Grows Stake in Disc Medicine, Inc. (NASDAQ:IRON)

Dimensional Fund Advisors LP increased its position in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 160.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 139,720 shares of the company's stock after acquiring an additional 86,154 shares during the period. Dimensional Fund Advisors LP owned approximately 0.47% of Disc Medicine worth $8,856,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new stake in Disc Medicine in the 4th quarter valued at approximately $5,479,000. Barclays PLC lifted its holdings in Disc Medicine by 123.7% in the third quarter. Barclays PLC now owns 40,145 shares of the company's stock worth $1,972,000 after buying an additional 22,202 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Disc Medicine in the fourth quarter worth approximately $5,579,000. KLP Kapitalforvaltning AS purchased a new stake in Disc Medicine during the 4th quarter valued at $235,000. Finally, Wells Fargo & Company MN raised its stake in shares of Disc Medicine by 60.2% during the 4th quarter. Wells Fargo & Company MN now owns 20,778 shares of the company's stock worth $1,317,000 after acquiring an additional 7,808 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Stifel Nicolaus upped their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. BMO Capital Markets increased their price objective on shares of Disc Medicine from $112.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday. Scotiabank boosted their price target on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Wedbush reaffirmed an "outperform" rating and set a $90.00 target price (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, HC Wainwright reiterated a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a report on Tuesday, January 21st. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $98.80.

Insider Buying and Selling

In other news, CFO Jean M. Franchi sold 3,136 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,162.88. Following the transaction, the chief financial officer now owns 69,530 shares of the company's stock, valued at approximately $3,794,947.40. This represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO John D. Quisel sold 5,574 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the transaction, the chief executive officer now owns 154,828 shares of the company's stock, valued at approximately $8,450,512.24. The trade was a 3.48% decrease in their position. The disclosure for this sale can be found here. Insiders sold 356,290 shares of company stock worth $19,336,901 in the last ninety days. Insiders own 4.24% of the company's stock.

Disc Medicine Stock Down 0.6%

NASDAQ:IRON traded down $0.26 during mid-day trading on Tuesday, hitting $46.35. 273,250 shares of the company traded hands, compared to its average volume of 350,265. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -11.65 and a beta of 0.77. Disc Medicine, Inc. has a one year low of $30.65 and a one year high of $68.73. The stock's fifty day moving average price is $46.72 and its 200-day moving average price is $54.99.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.03). Equities analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.